Sandra T Davidge Selected Research

mitoquinone

1/2020	Placenta-targeted treatment in hypoxic dams improves maturation and growth of fetal cardiomyocytes in vitro via the release of placental factors.
1/2019	Sex-Specific Effects of Nanoparticle-Encapsulated MitoQ (nMitoQ) Delivery to the Placenta in a Rat Model of Fetal Hypoxia.
1/2018	Maternal treatment with a placental-targeted antioxidant (MitoQ) impacts offspring cardiovascular function in a rat model of prenatal hypoxia.
1/2017	Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandra T Davidge Research Topics

Disease

23	Hypoxia (Hypoxemia) 12/2022 - 02/2005
19	Pre-Eclampsia (Preeclampsia) 01/2021 - 02/2002
16	Inflammation (Inflammations) 06/2022 - 06/2008
15	Hypertension (High Blood Pressure) 06/2022 - 03/2008
10	Cardiovascular Diseases (Cardiovascular Disease) 06/2022 - 07/2004
8	Atherosclerosis 01/2013 - 02/2002
6	Vascular Diseases (Vascular Disease) 07/2014 - 04/2004
5	Fetal Growth Retardation (Intrauterine Growth Retardation) 12/2015 - 08/2010
4	Body Weight (Weight, Body) 01/2020 - 02/2003
4	Insulin Resistance 10/2018 - 02/2011
4	Ischemia 01/2017 - 03/2006
3	Hypertrophy 03/2021 - 01/2017
3	Hyperglycemia 01/2015 - 11/2009
3	Vascular Remodeling 07/2014 - 05/2003
2	Fetal Hypoxia 01/2020 - 01/2019
2	Weight Gain 01/2020 - 01/2015
2	Fetal Weight 01/2020 - 01/2013
2	Gestational Diabetes (Gestational Diabetes Mellitus) 02/2017 - 01/2015
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2017 - 09/2011
2	Hypotension (Low Blood Pressure) 04/2013 - 07/2009
2	Fibrosis (Cirrhosis) 01/2013 - 03/2010
2	Glucose Intolerance 09/2011 - 02/2011
1	Obesity 10/2022
1	Carcinogenesis 04/2022
1	Neoplasms (Cancer) 04/2022
1	Neoplasm Metastasis (Metastasis) 04/2022
1	Hyperoxia 01/2021
1	Left Ventricular Dysfunction 01/2020
1	HELLP Syndrome 12/2018
1	Hemolysis 12/2018
1	Proteinuria 12/2018
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2018
1	Embryo Loss 01/2018

Drug/Important Bio-Agent (IBA)

10	Angiotensin IIIBA 06/2022 - 04/2004
10	Estrogens (Estrogen)FDA Link 01/2016 - 02/2003
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2018 - 01/2003
8	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2016 - 11/2005
7	Superoxides (Superoxide)IBA 01/2019 - 01/2010
7	ResveratrolIBA 01/2017 - 09/2011
6	Oxygen (Dioxygen)IBA 12/2022 - 01/2004
6	AntioxidantsIBA 01/2021 - 11/2009
6	Endothelin-1 (Endothelin 1)IBA 10/2013 - 02/2005
6	Matrix Metalloproteinases (MMPs)IBA 03/2010 - 02/2003
5	Peptides (Polypeptides)IBA 06/2022 - 07/2014
5	oxidized low density lipoproteinIBA 01/2020 - 02/2009
5	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2018 - 02/2005
5	CytokinesIBA 01/2018 - 04/2004
5	Peroxynitrous Acid (Peroxynitrite)IBA 01/2012 - 02/2002
4	LipidsIBA 01/2020 - 10/2009
4	mitoquinoneIBA 01/2020 - 01/2017
4	EnzymesIBA 12/2018 - 10/2009
4	Proteins (Proteins, Gene)FDA Link 09/2017 - 01/2003
4	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2014 - 01/2003
3	Insulin (Novolin)FDA Link 10/2018 - 02/2011
3	Methacholine Chloride (Methacholine)FDA Link 01/2018 - 09/2004
3	ConalbuminIBA 01/2017 - 09/2015
3	Nitric Oxide Synthase (NO Synthase)IBA 05/2016 - 10/2009
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 09/2015 - 04/2013
3	LectinsIBA 02/2015 - 05/2012
3	Matrix Metalloproteinase 2 (Gelatinase A)IBA 12/2013 - 01/2004
2	Antihypertensive Agents (Antihypertensives)IBA 03/2022 - 10/2016
2	Endothelins (Endothelin)IBA 01/2022 - 01/2003
2	CollagenIBA 01/2020 - 02/2003
2	salicylhydroxamic acid (SHAM)IBA 01/2020 - 09/2017
2	Glucose (Dextrose)FDA LinkGeneric 02/2017 - 01/2015
2	Metalloproteases (Metalloproteinases)IBA 01/2017 - 01/2005
2	Vasoconstrictor AgentsIBA 10/2016 - 11/2005
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2016 - 01/2012
2	Sildenafil Citrate (Viagra)FDA Link 12/2015 - 05/2012
2	tanshinoneIBA 01/2015 - 10/2009
2	Propofol (Diprivan)FDA LinkGeneric 04/2013 - 07/2009
2	AngiotensinsIBA 01/2013 - 01/2012
2	LDL Lipoproteins (beta Lipoproteins)IBA 05/2012 - 02/2009
2	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 09/2010 - 02/2009
2	ArginaseIBA 01/2010 - 10/2009
2	Tissue Inhibitor of Metalloproteinase-1IBA 01/2005 - 01/2004
2	Tissue Inhibitor of Metalloproteinase-2IBA 01/2005 - 01/2004
1	mesoglycanIBA 10/2022
1	peptide VIBA 06/2022
1	p38 Mitogen-Activated Protein KinasesIBA 06/2022
1	RNA-Induced Silencing ComplexIBA 04/2022
1	Protein Isoforms (Isoforms)IBA 04/2022
1	Protein Hydrolysates FDA Link 03/2022
1	Hemoglobins (Hemoglobin)IBA 03/2021
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2021
1	hemoglobin P (Hb P)IBA 01/2021
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021
1	CholesterolIBA 01/2020
1	Conditioned Culture MediaIBA 01/2020
1	LigandsIBA 01/2020
1	Folic Acid (Vitamin M)FDA LinkGeneric 12/2018
1	isoleucyl-prolyl-prolineIBA 10/2018
1	NF-kappa B (NF-kB)IBA 10/2018
1	indolepropanol phosphate (IPP)IBA 10/2018
1	valyl-prolyl-prolineIBA 10/2018
1	Isoantigens (Alloantigen)IBA 01/2018
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 09/2017

Therapy/Procedure

4	Therapeutics 04/2016 - 01/2013
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2015 - 10/2009
2	Hormone Replacement Therapy (Therapy, Hormone Replacement) 08/2009 - 07/2004